Physician profile
Reza Sutandi
NPI 1639146087
$5,296.34
in general payments reported to CMS, 2019-2025
23 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.37 · 2020: $46.75 · 2021: $45.98 · 2022: $25.01 · 2023: $726 · 2024: $4,236 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $1,739 · Travel and Lodging: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $1,739.01 |
| Travel and Lodging | $428.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,517.68 | 2024 | |
| Shield Therapeutics INC | $741.01 | 2023-2024 | Accrufer |
| Exeltis, USA INC. | $196.44 | 2023-2024 | Slynd |
| Sumitomo Pharma America, INC. | $98.37 | 2023-2024 | Myfembree |
| Biogen, INC. | $95.44 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $93.61 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $72.89 | 2023-2025 | |
| Abbvie INC. | $61.35 | 2020-2023 | Lo Loestrin Fe |
| Astellas Pharma US INC | $56.58 | 2023-2024 | Veozah |
| Hologic Sales and Service, LLC | $55.83 | 2023-2025 | Aptima, Fetal Fibronectin Enzyme Immunoassay |
| Pfizer INC. | $48.77 | 2024 | |
| Optumhealth Care Solutions, LLC | $33.46 | 2024-2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Baxter Healthcare | $30.70 | 2024 | Perclot |
| Alydia Health | $26.69 | 2021 | |
| Ethicon US, LLC | $25.01 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $24.96 | 2023 | |
| Allergan, INC. | $24.56 | 2019-2020 | |
| Heron Therapeutics, INC. | $20.57 | 2025 | Zynrelef |
| Convatec INC. | $18.63 | 2023 | |
| Minerva Surgical, INC | $18.37 | 2025 | |
| Daiichi Sankyo INC. | $16.61 | 2020 | |
| Organon LLC | $13.20 | 2024 | |
| Meditrina | $5.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reza Sutandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.